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Available online 25 June 2016Circulating tumor DNA (ctDNA) is emerging as a key potential biomarker for post-diagnosis surveillance but it
may also play a crucial role in the detection of pre-clinical cancer. Small-cell lung cancer (SCLC) is an excellent
candidate for early detection given there are no successful therapeutic options for late-stage disease, and it dis-
plays almost universal inactivation of TP53. We assessed the presence of TP53mutations in the cell-free DNA
(cfDNA) extracted from the plasma of 51 SCLC cases and 123 non-cancer controls. We identiﬁed mutations
using a pipeline speciﬁcally designed to accurately detect variants at very low fractions.We detected TP53muta-
tions in the cfDNA of 49% SCLC patients and 11.4% of non-cancer controls. When stratifying the 51 initial SCLC
cases by stage, TP53 mutations were detected in the cfDNA of 35.7% early-stage and 54.1% late-stage SCLC pa-
tients. The results in the controls were further replicated in 10.8% of an independent series of 102 non-cancer
controls. The detection of TP53mutations in 11% of the 225 non-cancer controls suggests that somatic mutations
in cfDNA among individuals without any cancer diagnosis is a common occurrence, and poses serious challenges
for the development of ctDNA screening tests.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Screening1. Introduction
Cell-free DNA (cfDNA) refers to nucleic acids detected in body ﬂuids
and are thought to arise from two sources: passive release through cell
death (Jahr et al., 2001), and active release by cell secretion (Stroun et
al., 2000). DNA from cancer cells also contributes to the total load of
cfDNA (Schwarzenbach et al., 2011), and the fraction of cfDNA that
comes from cancer cells is called circulating-tumor DNA (ctDNA).nP@iarc.fr (P. Brennan).
en access article under the CC BY-NCctDNA has been estimated to make up about 0.01%–1% of cfDNA for
early-stage disease, reaching over 40% for late-stage disease (Beaver et
al., 2014; Bettegowda et al., 2014; Couraud et al., 2014; Diehl et al.,
2007; Forshew et al., 2012; Newman et al., 2014; Sausen et al., 2015).
Despite its intrinsic limitations, including technical issues in the sample
collection, detection, and identiﬁcation of tumor origin, ctDNA is emerg-
ing as a key potential biomarker for monitoring response to treatment
and relapse (Dawson et al., 2013; Esposito et al., 2014; Forshew et al.,
2012; Garcia-Murillas et al., 2015; Murtaza et al., 2013; Roschewski et
al., 2015; Siravegna et al., 2015). The potential of ctDNA is not limited
to post-diagnosis surveillance but it may also play a crucial role in the
detection of pre-clinical cancer. If successful, this could be translated-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of small-cell lung cancer cases and controls from Russia, and additional
replication controls from Greece, Czech Republic, Italy, and Argentina.
Cases Controls Replication
controls
Origin (country)
Russia 51 123
Greece 9 (8.8%)
Czech Republic 14 (13.7%)
Italy 40 (39.2%)
Argentina 39 (38.2%)
Total 51 123 102
Age at diagnosis
b40 2
(3.9%)
2 (1.6%) 3 (2.9%)
40–49 4
(7.8%)
11
(8.9%)
15 (14.7%)
50–59 15
(29.4%)
42
(34.2%)
33 (32.4%)
60–69 22
(43.1%)
55
(44.7%)
33 (32.4%)
70+ 8
(15.7%)
13
(10.6%)
18 (17.7%)
Sex
Male 43
(84.3%)
107
(87.0%)
76 (74.5%)
Female 8
(15.7%)
16
(13.0%)
26 (25.5%)
Smoking status
Never 5
(9.8%)
35
(28.4%)
34 (33.4%)
Former 6
(11.8%)
28
(22.8%)
25 (24.5%)
Current 40
(78.4%)
60
(48.8%)
43 (42.1%)
Alcohol status
Never 30
(58.8%)
32
(26.0%)
16 (15.7%)
Former 4
(7.8%)
18
(14.6%)
14 (13.7%)
Current 17
(33.4%)
73
(59.4%)
72 (70.6%)
Tumor stage of cases
I 7
(13.7%)
II 7
(13.7%)
III 28
(54.9%)
IV 9
(17.6%)
Disease type of hospital controls
Infectious & parasitic diseases 0 (0.0%) 1 (1.0%)
Neoplasms 3 (2.4%) 0 (0.0%)
Endocrine, nutritional and metabolic diseases
and immunity disorders
6 (4.9%) 1 (1.0%)
Diseases of blood and blood-forming organs 2 (1.6%) 1 (1.0%)
Diseases of the nervous system and sense
organs
28
(22.8%)
6 (5.9%)
Diseases of the sense organs 0 (0.0%) 5 (4.9%)
Diseases of the circulatory system 25
(20.3%)
2 (2.0%)
Diseases of the respiratory system 3 (2.4%) 3 (2.9%)
Diseases of the digestive system 19
(15.4%)
19 (18.6%)
Diseases of the genitourinary system 19
(15.4%)
17 (16.7%)
Diseases of the skin and subcutaneous tissue 3 (2.4%) 2 (2.0%)
Diseases of the musculoskeletal system and
connective tissue
9 (7.3%) 18 (17.6%)
Symptoms, signs and ill-deﬁned conditions 0 (0.0%) 8 (7.8%)
Injury and poisoning 6 (4.9%) 18 (17.6%)
External causes 0 (0.0%) 1 (1.0%)
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that are typically diagnosed at a late stage, and for which survival is
poor, such as lung, pancreatic, or esophageal cancer (Brennan and
Wild, 2015). However, implementation of ctDNA tests that detect pre-
clinical disease in a non-symptomatic population will have to show an
extremely high speciﬁcity if they are to provide meaningful results, or
be part of a multi-modal screening program.
Very few studies have focused on the evaluation of ctDNA detection
in early-stage cancers (i.e. stage I-II tumors) with even less data avail-
able on the detection of ctDNA in blood samples from pre-symptomatic
cancer patients (Amant et al., 2015; Beaver et al., 2014; Bettegowda et
al., 2014; Garcia-Murillas et al., 2015; Gormally et al., 2006;
Jamal-Hanjani et al., 2016; Sausen et al., 2015); Table S1). In addition,
these studies have aimed to detect speciﬁc mutations in cfDNA (most
of them using digital droplet PCR) following previous assessment of
the tumor mutational proﬁle. This approach is only viable for cancers
with common hot-spot mutations and is not amenable for most screen-
ing purposes. This is because early detection of pre-clinical cancer re-
quires variant detection to be done without prior knowledge from
tumor tissue of the expected mutations. Another limitation of these
studies is the major assumption that circulating-mutated fragments
would be absent (or very rare) in individuals without cancer. Demon-
strating that any ctDNA detection marker has a speciﬁcity close to
100% would be of fundamental importance for large-scale utility in an
asymptomatic population (Wentzensen and Wacholder, 2013).
Small-cell lung cancer (SCLC) accounts for about 15% of all lung tu-
mors andhas a 5-year survival below5%.While SCLC tumors are initially
sensitive to chemotherapy, they invariably relapse with a resistant and
deadly disease. We and others have found that, contrary to lung adeno-
carcinomas and squamous-cell lung carcinomas,mutations in therapeu-
tic targets are rare in SCLC (George et al., 2015; Peifer et al., 2012; Rudin
et al., 2012). TP53 is inactivated in virtually all SCLC cases, and TP53mu-
tations are known to be an early event in the development of this dis-
ease. Given the almost uniform presence of TP53 mutations in SCLC,
we have investigated towhat extentmutations in this gene can be iden-
tiﬁed in the cfDNA of patients with SCLC tumors. In addition, we have
also assessed two independent series of non-cancer controls to evaluate
the speciﬁcity of the approach.
2. Material and Methods
2.1. Study Population
Small-cell lung cancer (SCLC) patients and controls were recruited
through an IARC case-control study coordinated in Moscow from 2006
to 2012 (Wozniak et al., 2015). Cases were incident cancer patients col-
lected from the Russian N.N. Blokhin Cancer Research Centre and the
Moscow City Clinical Oncology Dispensary. The staging of the SCLC
cases is based on the recent recommendations of the International Asso-
ciation for the Study of Lung Cancer (IASLC) (Nicholson et al., 2016).
Controls were recruited from individuals visiting two Moscow general
hospitals for disorders unrelated to lung cancer and its associated risk
factors (Table 1). The controls were matched for age, sex, and smoking
status. All study participants provided written-informed consent and
participated in an interview. Peripheral blood was collected in EDTA
tubes at the time of interview and processed as rapidly as possible (gen-
erally within 2 h). For cases, blood draw was performed before surgery
and any adjuvant treatment. Plasma samples were isolated by centrifu-
gation of whole blood at 2000 ×g for 10min at room temperature. Sam-
ples were stored at−80 °C. All specimens were obtained in accordance
with the declaration of Helsinki guidelines and were approved by the
local Institutional Review Board and the IARC Ethics Committee. A
total of 52 SCLC cases and 165 controls were initially included but
only 51 SCLC and 123 controls passed the sequencing QC criteria (see
Sequencing Data Analyses, Annotation, and Filters), and were therefore
included in down-stream analyses.
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fragments in non-cancer controls, 114 additional controls were re-
trieved from two large multicenter case-control studies coordinated
by IARC. Onewas a study on alcohol-related cancers and genetic suscep-
tibility in Europe (the ARCAGE study) that was conducted from 2002 to
2005 and from which we included hospital-based controls recruited in
Prague (Czech Republic), Athens (Greece), Aviano, Padova and Turin
(Italy). The second was the Latin American study of head and neck can-
cer conducted from 1998 to 2002 and fromwhichwe selected hospital-
based controls from two institutions in Buenos Aires (Argentina). Addi-
tional details of the 2 largemulticenter case-control studies are included
elsewhere (Lagiou et al., 2009; Ribeiro et al., 2011). Out of the 114 con-
trols initially included, 102 passed the sequencing QC criteria (see
Sequencing Data Analyses, Annotation, and Filters), and were therefore
included in down-stream analyses.
2.2. cfDNA Extraction
cfDNA was extracted from 0.8–1.3 mL of plasma using the
QIAamp DNA Circulating Nucleic Acid kit (Qiagen) following
manufacturer's instructions. cfDNA was eluted into 100 μL of elution
buffer and quantiﬁed with the Qubit DNA high-sensitivity assay kit
(Invitrogen Corporation). Details regarding amount of cfDNA are in-
cluded in the Table S2.
2.3. Primer Design and Ampliﬁcation of Targets
Twenty-one amplicons of 150 bp in size were designed (Euroﬁns
Genomics Ebersberg, Germany) to cover exons 2 to 10 of TP53. The
GeneRead DNAseq Panel PCR Kit V2 (Qiagen) was used for target en-
richment. A validated in-house protocol was used to set up multiplex
PCRs in 10 μL reaction volume, containing 5 ng cfDNA, 60 nM of primer
pool and 0.73 μL of HotStarTaq enzyme. The experiments were carried
out in two physically isolated laboratory spaces: one for sample prepa-
ration and another one for post-ampliﬁcation steps. Ampliﬁcation was
carried out in a 96-well format plates DNA engine Tetrad 2 Peltier Ther-
mal Cycler (BIORAD) as follows: 15min at 95 °C and 30 cycles of 15 s at
95 °C and 2 min at 60 °C and 10 min at 72 °C.
2.4. Library Preparation and Sequencing
Following target enrichment, PCR products were puriﬁed using
Serapure beads (prepared in-house and produced by ThermoFisher
Scientiﬁc Inc.). A ratio of 2:1 of Serapure beads to PCR products was
used. Puriﬁed amplicons were quantiﬁed with the Qubit DNA high-
sensitivity assay kit (Invitrogen Corporation). Library preparation
was done using 150 ng of puriﬁed PCR products and the NEBNext
Fast DNA Library Prep Set for Ion Torrent (New England Biolabs, Ips-
wich, MA, USA) following manufacturer's instructions. Amplicons
were end-repaired and ligated to the speciﬁc adapters and individual
barcodes (designed in-house and produced by Euroﬁns MWG Oper-
on, Ebersberg, Germany). Libraries were cleaned up, ampliﬁedwith a
ﬁnal step of 6 PCR cycles, pooled in an equimolar way and loaded
onto a 2% agarose gel and subjected to an electrophoresis at 150 V
for 1.5 h. Fragments of 180–220 bp in size were selected and the
pooled DNA library was recovered from the gel using the QIAquik
Gel Extraction kit (Qiagen). The quality and quantity of the library
was then assessed on the Agilent 2100 Bioanalyzer on-chip electro-
phoresis (Agilent Technologies, USA) for the absence of possible
adapter dimers and heterodimers. The pooled libraries were se-
quenced on the Ion Torrent™ Proton Sequencer (Life Technologies
Corp., USA) aiming for deep coverage (5,000×), using the Ion PI™
Hi-Q™ OT2 200 Kit and the Ion PI™ Hi-Q™ Sequencing 200 Kit
with the Ion PI chip V3 (Life Technologies Corp., USA), following
the manufacture's protocols.2.5. Technical Duplication
Technical duplicates were undertaken for each sample including
ampliﬁcation, library preparation, and sequencing. Each technical dupli-
cate pair was assessed on separate plates to limit the possibility of a
contamination.
2.6. Sequencing Data Analyses, Annotation, and Filters
Short reads were aligned to the hg19 human reference genome and
BAM ﬁles were generated using the Torrent Suite software (v4.4.2) with
default parameters. Readswith amapping quality below 20were exclud-
ed from subsequent analysis. We also excluded those libraries for which
the on-target median coverage was signiﬁcantly lower in comparison to
the other libraries sequenced in the same batch. On-target median cover-
age for both libraries is shown in Table S2.
For the calling of variants we used Needlestack, a recently developed
ultra-sensitive variant caller, which estimates the distribution of se-
quencing errors across multiple samples to reliably identify variants
present in very low proportion (https://github.com/IARCbioinfo/
needlestack) (unpublished data; Delhomme et al.). Contrary to most
existing algorithms, Needlestack can deal with both single nucleotide
substitutions (SNVs) and short indels. At each position and for each can-
didate variant, sequencing errors are modeled using a robust negative
binomial regression (Aeberhard et al., 2014), with a linear link and a
zero intercept. True variants are outliers from this error model (Fig.
1a). The robust estimator of the over-dispersion parameter avoids bias
due to these outliers (Aeberhard et al., 2014). For each sample a p-
value against the null hypothesis of being a sequencing error is calculat-
ed, and further transformed into a q-value using the Benjamini and
Hochberg false-discovery rate control method (Benjamini and Yosef,
1995). Q-values are reported as a Phred-scale quality score: Q =−10
log10(q-value), and we used a threshold of Q N 50 to call variants. For
each variant, we also calculated the relative variant strand bias deﬁned
by:
RVSB ¼ max AOpDPm;AOmDPp
 
AOpDPm þ AOmDPp:
where DP and AO denote respectively the total number of reads and the
number of reads matching the candidate variant, with the subscripts p
and m referring to the forward and reverse strands respectively. In the
complete absence of strand bias, RVSB = 0.5 and AOp/AOm = DPp/DPm,
whereas for a completely biased variant, RVSB= 1. We ﬁltered out vari-
ants with RVSB N 0.85.
Variant calls were annotated using ANNOVAR (Yang and Wang,
2015). We only considered meaningful TP53 mutations those that
matched the following criteria: the mutation has already been reported
in COSMIC and themutation is a nonsense, indel, splicing or a missense
variant that is classiﬁed as deleterious by SIFT or Polyphen.
2.7. Analyses of Technical Duplicates
While Needlestack models recurring errors, rare errors such as those
generated by the DNA polymerase will be identiﬁed as variants. Such er-
rors will be generally speciﬁc to a particular preparation. To ﬁlter out
these rare errors, we required each of the individual's technical duplicate
to be a Needlestack outlier (Fig. 1a). Additionally, we identiﬁed and ex-
cluded a few genomic positions that show a particularly high proportion
(N10%) of these errors (i.e. higher than the estimated sequencing error
rate, but not always replicable in two independent preparations).
2.8. Statistical Analyses
Effect of age, smoking, and alcohol status on the presence of TP53
mutations was assessed using logistic regression adjusting one for the
Fig. 1. Characteristics of TP53 mutations in cases and controls (a) Two examples of variants called using Needlestack's regression model of sequencing error. Each dot represents a
sequenced library (two dots per sample) colored according to its phred-scaled q-value. The black regression line shows the estimated sequencing-error rate along with the 99%
conﬁdence interval (black dotted lines) containing samples. Colored-dotted lines correspond to the limits of regions deﬁned for different signiﬁcance q-value thresholds. Both
technical duplicates appear as outliers from the regression (in red), and are therefore classiﬁed as carrying the given mutation; (b) Percentage of TP53mutated samples in the cfDNA
of Russian cases and controls, and replication controls; (c) Distribution of TP53mutations found in SCLC tumors (George et al., 2015) and in our series of cases and controls across the
different p53 protein domains; (d) Type of mutations and functional impact of missense ones based on the IARC TP53 database: F (functional), PF (partially functional), NF (non-
functional); (e) Percentage of allelic fractions of the TP53 mutations detected in the cfDNA of Russian cases and controls, and replication controls. The whiskers represent the
minimum and maximum values.
120 L. Fernandez-Cuesta et al. / EBioMedicine 10 (2016) 117–123others. Effect of case-status on the presence of TP53 mutations was
assessed using unadjusted logistic regression. p-Values to test the differ-
ences between the pattern of mutations in cases and controls arederived from Pearson's chi-square tests. All the analyses were conduct-
ed using SAS 9.4. For comparison of allelic fractions, we log-transformed
the data and performed a t-test (2 tailed, unequal variance).
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The characteristics of the cases and controls are shown in Table 1.
We detected 31 TP53 mutations in 25 SCLC patients (49%, 25/51).
When the 51 initial SCLC cases were stratiﬁed by stage, we found that
35.7% (5/14) of the stage I–II and 54.1% (20/37) of the stage III–IV, car-
ried detectable TP53mutations in their cfDNA (Fig. 1b). While statisti-
cally signiﬁcant in cases versus controls (p-value = 6 × 10−9), 18 TP53
mutations were detected in 14 of the Russian non-cancer controls
(11.4%, 14/123). The signiﬁcance was also maintained when stratifying
by stage (stage I–II versus controls, p-value = 0.012; stage III–IV versus
controls, p-value = 1 × 10−8). We replicated these observations in an
independent series of 102 controls, and found a comparable proportion
of TP53mutated samples (10.8%, 13 TP53mutations in 11 controls).
Similarly to what is expected for TP53mutations present in cancer,
most of the mutations in cases and controls altered amino acids coding
for the TP53 DNA-binding domain, which is critical for the
transactivation activity of this gene (Fig. 1c). We next evaluated the
characteristics of the mutations found in cases versus controls. Chi-
square test analysis showed that there was a statistically signiﬁcant dif-
ference between the mutational pattern found in cases versus controls
(p-value=0.008). The fraction of nonsense, indel, or splicingmutations
found in the cases was similar to that previously reported for SCLC tu-
mors (George et al., 2015) (35.5% versus 37% respectively), whereas
this proportion was slightly lower in controls (22.2% in the Russian,
and 7.7% in the replication controls; Fig. 1d).We used the IARC TP53 da-
tabase to classify the missense mutations in functional, partially func-
tional, or non-functional based on the in vitro transcriptional activity
of the resulting protein.Mostmissensemutations found in SCLC tumors
(George et al., 2015) (92.6%) and cfDNA from cases (100%) were classi-
ﬁed as resulting in a non-functional protein. However, controls had a
higher proportion of missense mutations that retained some transcrip-
tional activity (~30%; Fig. 1d).
We also compared the allelic fractions (AFs) of the TP53mutations
found in the cfDNA of cases and controls. The AFs for a given mutation
were similar in the two independent libraries, demonstrating the repro-
ducibility of the assay (Table S3, S4, and S5). The AFs for the cases
ranged from 0.12% to 84.81% (median 4.6%). In the Russian controls
the AFs ranged from 0.19% to 84.94% (median 1.2%), and in the replica-
tion controls they ranged from 0.02% to 63.74% (median 0.5%) (Fig. 1e).
The statistically signiﬁcant difference in the AFs between cases and con-
trols (p-value = 4 × 10−4) is explained by the presence of late-stage
SCLC tumors, since the median AF of the TP53 mutations detected in
the ﬁve stage I–II SCLC (0.9%) is not statistically different from that
found in controls (p-value = 0.64), while it differed from the median
AF of stage III-IV SCLC tumors (8.2%; p-value = 2 × 10−6; Fig. 1e).
Finally, we sequenced the DNA extracted from thewhite-blood cells
(WBC) of 39 cfDNA TP53-positive patients, from which material was
available (19 cases and 20 controls). Five cfDNA TP53mutations (from
one case and four controls)were detected in theWBCDNA, with similar
AFs to those found in the cfDNA (Table 2). For one control (MLT-14), the
AFs in both cfDNA and WBC DNA were around 50%, being consistent
with a heterozygous germ-line variant. The other four mutations were
detected at AFs consistent with a somatic origin (AFs below 11%) in
both cfDNA and WBC DNA (Table S2).Table 2
Overview of the cfDNAmutations also detected in the white-blood cells (WBC) DNA, and
their corresponding allelic fractions in each technical duplicate (AFs in %).
Sample TP53mutation
AFs detected in
cfDNA
AFs detected in
WBC
SCLC-21 p.Y220C 0.90 1.27 0.50 0.70
MLT-6 p.R175G 4.09 4.41 4.40 4.50
MLT-14 p.G154S 47.17 50.58 52.10 54.90
ARG-1 p.R273C 5.22 5.58 7.30 10.40
ITA-8 p.V272M 0.78 0.80 0.90 1.40Taken altogether, cancer-like TP53mutations were identiﬁed in 25
of the 225 non-cancer controls analyzed in this study (11.1%). We
checked if the presence of TP53mutations in the controlswas correlated
with age, smoking status, or alcohol (adjusting one for the other), but
none of these factors was found to be associated.4. Discussion
Inactivation of TP53 by mutation has been reported to occur in over
90% of SCLC cases (George et al., 2015). In this studywewere able to de-
tect TP53mutations in the cfDNA of 49% SCLC patients and, when strat-
ifying by stage, in the cfDNA of 35.7% early-stage cases. These
proportions matched those reported for other cancer types
(Bettegowda et al., 2014). Unfortunately, we did not have the corre-
spondent tumors to conﬁrm that the TP53 mutations detected in the
cfDNA originate from the SCLC tumors. However, our method detected
TP53mutations in 60% of the cfDNA samples of an independent French
series of 10 SCLC patients (all of them carrying TP53 somatic mutations
in their tumors). Importantly, each of the TP53mutations found in the
cfDNA matched the one found in the SCLC tumor (data not shown).
We also observed cfDNA TP53-mutated fragments in 11.4% of 123
matched non-cancer controls. Acknowledging the potential for bias in
our selection of controls (such as differential performance in QC criteria
or cfDNA amount, between cases and controls), we screened a second
series of 102 non-cancer controls, and found a comparable proportion
of TP53mutated samples in this independent group (13 TP53mutations
in 11 controls, 10.8%). Altogether, the detection of TP53 mutations in
11.1% of the 225 non-cancer controls, from two independent groups of
samples, suggests that the presence of circulating-mutated fragments
among individuals without any diagnosed cancer is a common occur-
rence, and poses serious challenges for the development of ctDNA
screening tests for the early detection of cancer.
Only two other studies have explored the potential presence of cir-
culating-mutated fragments in non-cancer subjects. A study within
the EPIC prospective cohort (GENAIR) that used blood samples from
controls, found that KRAS and TP53 mutations were detectable in the
cfDNA of 1% and 3.2% healthy subjects, respectively, without a cancer di-
agnoses ﬁve years subsequent to blood draw (Gormally et al., 2006).
The higher percentage of TP53-positive controls in our analyses is likely
to be explained by the fact that these analyses within EPIC were under-
taken using DHPLC (denaturing high-pressure liquid chromatography)
and Sanger sequencing, and these techniques are less sensitive and
only allow for detection of mutations with allelic fractions of 3% or
more. Further, only TP53 exons ﬁve to ninewere analyzed. If we limited
our analysis to mutations from exons ﬁve to nine and AFs greater that
3%, we would have found a comparable number of TP53-positive con-
trols (2.7%, 6/225). More recently, Krimmel and colleagues have report-
ed extremely low-frequency cancer-like TP53 mutations in the
peritoneal ﬂuid from both women with ovarian cancer and those with
benign lesions, using duplex sequencing (Krimmel et al., 2016). They
also showed that low frequency TP53 mutagenesis increases with age
and cancer. Overall, these results support the need for further ctDNA
studies to incorporate series of non-cancer controls in order to improve
validation of detection and analysis techniques.
A potential limitation of our studywas the use of hospital controls as
proxies of healthy people. Controls were admitted for a wide variety of
routine conditions unrelated to tobacco and it is implausible that a high
proportion of the controls with a detectable damaging TP53 mutation
developed a cancer in the short term. However, we cannot exclude
this occurring in a small number of controls nor enriching for non-can-
cer diseaseswith unknown impact on the presence of circulating-tumor
fragments. Nevertheless, as noted above, the prevalence of TP53muta-
tions in our study is approximately equal to that of GENAIR (when ap-
plying the same detection thresholds). Prospective cohorts may help
to overcome the limitations of using hospital controls and also help to
122 L. Fernandez-Cuesta et al. / EBioMedicine 10 (2016) 117–123determine at what point in the development of the disease is ctDNA de-
tectable in blood, and its correlation with a plausible diagnosis.
The source of circulating-mutated fragments in the cfDNA of appar-
ently healthy people is still unknown. There is, however, accumulating
evidence that clonal expansions are more frequent than originally
thought. Martincorena and colleagues estimated that there are 9.5
clones per cm2 of normal human skin carrying a driver mutation in
TP53 in a selected population for high-sun exposure (Martincorena
and Campbell, 2015). Such clonal expansions might act as a reservoir
of circulating-mutated fragments in cfDNA. In addition, several studies
have shown that a subset of normal individuals could undergo clonal
hematopoiesis with mutations in driver genes (Genovese et al., 2014;
Jacobs et al., 2012; Jaiswal et al., 2014; Laurie et al., 2012; Wong et al.,
2015; Xie et al., 2014). Consistent with this, we observed 4 cfDNA
TP53 mutations that appeared to be from clonal expansions in WBC.
We also noted 2 TP53mutations in one SCLC case, apparently from dif-
ferent organs; one originating from WBC, the second we assume from
the SCLC tumor. Such ambiguity around the tissue of origin of the circu-
lating-mutated fragments adds another layer of complexity when using
ctDNA for early detection.
The potential of ctDNA for early diagnosis of cancer is an area of
much interest (The Lancet Oncology, 2016). While implementation in
a screening settingwill undoubtedly requiremore sensitive and speciﬁc
tests as well as validation in pre-diagnostic blood samples, the unex-
pected presence of known cancer mutations in cfDNA among non-can-
cer controls represents an important challenge.
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